FrancophonIA/ELRC3.0 huggingface dataset:
English: Through 48 weeks in the GEMINI-1 and GEMINI-2 studies, no cases of emergent resistance to the integrase- or NRTI-class were seen in either the DTG+3TC or comparator DTG+ TDF/FTC arms.
Danish: Der blev gennem 48 uger i GEMINI-1 og GEMINI-2-studierne ikke set nogen tilfælde af fremskreden resistens over for integrase- eller NRTI-klassen i hverken DTG + 3TC eller komparator DTG + TDF/FTC-armene.
English: In a juvenile toxicity study in rats, dolutegravir administration resulted in two preweanling deaths at 75 mg/kg/day.
Danish: I et toksicitetsstudie hos unge rotter resulterede administration af dolutegravir i to tilfælde af død i præafvænningsperioden ved en dosis på 75 mg/kg/dag.
English: The decision to use dolutegravir for such patients should be informed by the integrase resistance pattern (see section 5.1).
Danish: Beslutningen om at anvende dolutegravir til sådanne patienter bør være kvalificeret af mønsteret på integraseresistensen (se pkt.
English: No data are available in subjects receiving dialysis although differences in pharmacokinetics are not expected in this population (see section 5.2).
Danish: Der er ingen tilgængelige data om personer i dialysebehandling, men der forventes ikke en anderledes farmakokinetik hos denne population (se pkt.
English: The efficacy of dolutegravir in combination with lamivudine in adults is supported by 48-week primary endpoint data from two identical 148-week, randomised, multicentre, double-blind, non-inferiority studies GEMINI-1 (204861) and GEMINI-2 (205543).
Danish: Virkningen af dolutegravir i kombination med lamivudin hos voksne er understøttet af 48-ugers primære endepunktsdata fra to identiske 148-ugers, randomiserede, multicenter, dobbeltblindede, non-ikke-inferioritetsstudier, GEMINI-1 (204861) og GEMINI-2 (205543).
English: • The usual dose is one 50 mg tablet once a day.
Danish: • Den sædvanlige dosis er en 50 mg tablet én gang daglig.
English: 15 to less than 20
Danish: 15 op til 20
English: • oxcarbazepine and carbamazepine, to treat epilepsy or bipolar disorder
Danish: • oxcarbamazepin og carbamazepin, til behandling af epilepsi eller bipolar lidelse (sindslidelse).
English: In patients with prior failed therapies, but naïve to the integrase class (SAILING study), integrase inhibitor substitutions were observed in 4/354 patients (follow-up 48 weeks) treated with dolutegravir, which was given in combination with an investigator selected background regimen (BR).
Danish: Hos patienter med tidligere behandlingssvigt, men som var naive over for integrasehæmmere (studie SAILING), blev der observeret integrasehæmmer-substitutioner hos 4 ud af 354 patienter (opfølgning på 48 uger), som blev behandlet med dolutegravir kombineret med et af investigator udvalgt baggrundsregime (BR).
English: Co-administration with dofetilide (see section 4.5).
Danish: Administration samtidigt med dofetilid (se pkt.
English: Co-administration of dolutegravir and other medicinal products that inhibit these enzymes may increase dolutegravir plasma concentration (see Table 2).
Danish: Samtidig administration af dolutegravir og andre lægemidler, der hæmmer disse enzymer kan øge plasmakoncentrationen af dolutegravir (se tabel 2).
English: - The other ingredients are mannitol (E421), microcrystalline cellulose, povidone (K29/32), sodium starch glycolate, sodium stearyl fumarate, polyvinyl alcohol-partially hydrolyzed, titanium dioxide (E171), macrogol, talc and for 25 and 50 mg tablets, iron oxide yellow (E172).
Danish: - Øvrige indholdsstoffer: mannitol (E421), mikrokrystallinsk cellulose, povidon (K29/32), natriumstivelsesglycolat, natriumstearylfumarat, polyvinylalkohol - delvist hydrolyseret, titandioxid (E171), macrogol, talcum og for 25 og 50 mg tabletterne, gult jernoxid (E172).
English: Following oral administration of tablet formulations, in general, dolutegravir exhibited nonlinear pharmacokinetics with less than dose-proportional increases in plasma exposure from 2 to 100 mg; however increase in dolutegravir exposure appears dose proportional from 25 mg to 50 mg for the tablet formulation.
Danish: Efter oral administration af tabletformuleringer havde dolutegravir generelt en non-lineær farmakokinetik med mindre end dosisproportionale øgninger i plasmaeksponeringen fra 2-100 mg; øgningen i eksponeringen for dolutegravir synes dog at være dosisproportional fra 25 mg til 50 mg for tabletformuleringen.
English: The efficacy of dolutegravir in HIV-infected, therapy naïve subjects is based on the analyses of 96-week data from two randomized, international, double-blind, active-controlled trials, SPRING-2 (ING113086) and SINGLE (ING114467).
Danish: Dolutegravirs virkning hos hiv-inficerede, behandlingsnaive personer er baseret på analyserne af 96-ugers data fra to randomiserede, internationale, dobbeltblindede, aktivt-kontrollerede studier, SPRING-2 (ING113086) og SINGLE (ING114467).
English: Analgesics Methadone
Danish: Analgetika Methadon
English: Tivicay can be taken with or without food (see section 5.2).
Danish: Tivicay kan tages sammen med eller uden mad (se pkt.
English: In a Phase I/II 48 week multicentre, open-label study (P1093/ING112578), the pharmacokinetic parameters, safety, tolerability and efficacy of Tivicay has been evaluated in combination regimens in HIV-1 infected, treatment-experienced, INI naive children and adolescents (6 to less than 18 years of age).
Danish: I et ublindet fase I/II-multicenterstudie af 48 ugers varighed (P1093/ING112578) er Tivicays farmakokinetiske parametre, sikkerhed, tolerabilitet og effekt blevet vurderet i kombinationsregime hos hiv 1-inficerede, behandlingserfarne, INI-naive børn og unge (6 år til under 18 år).
English: Treatment emergent integrase resistance typically appeared in patients with a history of the Q148-mutation (baseline or historic).
Danish: Under behandlingen opstod der typisk integraseresistens hos patienter med Q148-mutationen i anamnesen (ved baseline eller historisk).
English: Swallow the tablet with some liquid.
Danish: Synk tabletterne med væske.
English: Pharmacokinetic data for dolutegravir in subjects >65 years of age are limited.
Danish: Mængden af farmakokinetiske data om anvendelse af dolutegravir til personer > 65 år er begrænset.
English: → Talk to your doctor for further advice on taking calcium supplements, iron supplements or multivitamins with Tivicay.
Danish:  Tal med lægen for yderligere råd om, hvordan du skal tage calciumtilskud, jerntilskud eller multivitaminer sammen med Tivicay.
English: Dolutegravir ↓ (Not studied, decrease expected due to induction of UGT1A1 and CYP3A enzymes, a similar reduction in exposure as observed with carbamazepine is expected)
Danish: Dolutegravir  (Ikke undersøgt, fald er forventet pga. induktion af UGT1A1 og CYP3Aenzymer, en lignende reduktion i eksponering som observeret for carbamazepin forventes)
English: Very common Nausea Very common Diarrhoea Common Vomiting Common Flatulence Common Upper abdominal pain Common Abdominal pain Common Abdominal discomfort
Danish: Almindelig Opkastning Almindelig Flatulens Almindelig Smerter i den øvre del af abdomen Almindelig Abdominalsmerter Almindelig Abdominalt ubehag Lever og galdeveje Ikke almindelig
English: Based on in vivo and/or in vitro data, dolutegravir is not expected to affect the pharmacokinetics of medicinal products that are substrates of any major enzyme or transporter such as CYP3A4, CYP2C9 and P-gp (for more information see section 5.2).
Danish: På baggrund af in vivo og/eller in vitro data forventes dolutegravir ikke at påvirke farmakokinetikken af lægemidler, der er substrater for vigtige enzymer eller transportere, som f.eks. CYP3A4, CYP2C9 og P-gp (se pkt.
English: • difficulty breathing In rare cases, as the immune system becomes stronger, it can also attack healthy body tissue (autoimmune disorders).
Danish: I sjældne tilfælde kan immunsystemet, efterhånden som det bliver stærkere, også angribe raskt kropsvæv (autoimmune forstyrrelser).
English: 50 mg once daily
Danish: 50 mg én gang daglig
English: Particular diligence should be applied in initiating or maintaining effective hepatitis B therapy (referring to treatment guidelines) when starting dolutegravir-based therapy in hepatitis B co-infected patients (see section 4.8).
Danish: Der bør udvises særlig omhyggelighed ved indledning eller vedligeholdelse af effektiv behandling mod hepatitis B (under henvisning til retningslinjerne for behandling), når dolutegravir-baseret behandling påbegyndes hos patienter, der er co-inficeret med hepatitis B-virus (se pkt.
English: Nucleoside Reverse Transcriptase Inhibitors Tenofovir
Danish: Nukleosid revers transskriptase-hæmmere Tenofovir
English: GI intolerance in monkeys occurred at 15 times the human mg/kg equivalent dose (based on a 50 kg human), and 5 times the human mg/m2 equivalent dose for a clinical dose of 50 mg twice daily.
Danish: GI intolerance hos aber forekom ved 15 gange den ækvivalente humane dosis udtrykt i mg/kg (baseret på et menneske på 50 kg) og ved 5 gange den ækvivalente humane dosis udtrykt i mg/m2 for en klinisk dosis på 50 mg to gange daglig.
English: Bioavailability of dolutegravir depends on meal content: low, moderate, and high fat meals increased dolutegravir AUC(0-∞) by 33%, 41%, and 66%, increased Cmax by 46%, 52%, and 67%, prolonged Tmax to 3, 4, and 5 hours from 2 hours under fasted conditions, respectively.
Danish: Dolutegravirs biotilgængelighed afhænger af måltidets indhold: måltider med lavt, moderat og højt fedtindhold øgede dolutegravirs AUC(0-) med henholdsvis 33 %, 41 % og 66 %, øgede Cmax med henholdsvis 46 %, 52 % og 67 % og forlængede Tmax til henholdsvis 3, 4 og 5 timer i forhold til 2 timer ved faste.
English: In vitro, dolutegravir demonstrated no direct, or weak inhibition (IC50>50 μM) of the enzymes cytochrome P450 (CYP)1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6 CYP3A, uridine diphosphate glucuronosyl transferase (UGT)1A1 or UGT2B7, or the transporters Pgp, BCRP, BSEP, OATP1B1, OATP1B3, OCT1, MATE2-K, MRP2 or MRP4.
Danish: In vitro har dolutegravir ikke direkte, eller kun svagt, vist hæmning (IC50>50 µM) af enzymerne CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP3A, uridindifosfatglukuronosyltransferase (UGT)1A1 eller UGT2B7, eller transporterne Pgp, BCRP, BSEP, OATP1B1, OATP1B3, OCT1, MATE2-K, MRP2 eller MRP4.
English: Tivicay contains the active ingredient dolutegravir.
Danish: Tivicay indeholder det aktive stof dolutegravir.
English: Protease Inhibitors Atazanavir
Danish: Proteasehæmmere Atazanavir
English: The unbound fraction of dolutegravir in plasma is increased at low levels of serum albumin (<35 g/L) as seen in subjects with moderate hepatic impairment.
Danish: Den ubundne fraktion af dolutegravir i plasma øges ved lave niveauer af serumalbumin (< 35 g/l), som der er set hos personer med moderat nedsat leverfunktion.
English: No dose adjustment is necessary in the absence of integrase class resistance.
Danish: Det er ikke nødvendigt at justere dosis ved fravær af integrasehæmmerresistens.
English: The safety and efficacy of dolutegravir in children aged less than 6 years or weighing less than 15 kg have not yet been established.
Danish: Dolutegravirs sikkerhed og virkning hos børn under 6 år, eller som vejer under 15 kg, er endnu ikke klarlagt.
English: Tivicay can make you dizzy and have other side effects that make you less alert.
Danish: Trafik- og arbejdssikkerhed Tivicay kan gøre dig svimmel og give andre bivirkninger, som gør dig mindre opmærksom.
English: Other agents Antiarrhythmics Dofetilide
Danish: Andre midler Antiarytmika Dofetilid
English: At 96 weeks, virologic suppression in the dolutegravir group (80%) was superior to the DRV/r group (68%), (adjusted treatment difference [DTG-(DRV+RTV)]: 12.4%; 95% CI: [4.7, 20.2].
Danish: Virologisk suppression i dolutegravir-gruppen (80 %) var superior i forhold til DRV/r-gruppen (68 %) efter 96 uger (justeret behandlingsforskel [DTG-(DRV+RTV)]: 12,4 ; 95 % CI: [4,7, 20,2]).
English: Warnings and precautions Look out for important symptoms
Danish: Hold øje med vigtige symptomer
English: If you get any symptoms of infection and inflammation or if you notice any of the symptoms above:
Danish: Hvis du får nogle symptomer på infektion og betændelse, eller hvis du bemærker nogen af ovennævnte symptomer:  Fortæl det omgående til lægen.
English: The 50 mg dose should be taken as a single 50 mg tablet.
Danish: Dosis på 50 mg skal tages som én enkelt 50 mg tablet.
English: At week 48, 12/30 (40%) subjects had HIV-1 RNA <50 copies/mL (ITT-E, Snapshot algorithm).
Danish: Ved uge 48 havde 12 ud af 30 (40 %) patienter hiv-1-RNA < 50 kopier/ml (ITT-E, snapshot-algoritme).
English: Vistor hf. Sími: + 354 535 7000
Danish: Sími: + 354 535 7000
English: In a meta-analysis using pharmacogenomics samples collected in clinical studies in healthy subjects, subjects with UGT1A1 (n=7) genotypes conferring poor dolutegravir metabolism had a 32% lower clearance of dolutegravir and 46% higher AUC compared with subjects with genotypes associated with normal metabolism via UGT1A1 (n=41).
Danish: I en metaanalyse, hvor der blev brugt farmakogenomiske prøver indsamlet i kliniske studier af raske personer, havde personer med genotyper, der medførte dårlig metabolisering af dolutegravir via UGT1A1 (n = 7), en 32 % lavere clearance af dolutegravir og et 46 % større AUC sammenlignet med personer med genotyper, der var forbundet med normal metabolisering via UGT1A1 (n = 41).
English: 25 mg once daily
Danish: 25 mg én gang daglig
English: In Phase III studies patients with hepatitis B and/or C co-infection were permitted to enrol provided that baseline liver chemistry tests did not exceed 5 times the upper limit of normal (ULN).
Danish: Patienter, der var co-inficeret med hepatitis B- og/eller C-virus, fik mulighed for at blive inkluderet i fase IIIstudier, forudsat at resultaterne af deres leverkemianalyser ved baseline ikke oversteg 5 gange den øvre normalgrænse (ULN).
English: In a combined analysis of VIKING-3 and VIKING-4 (n=186, VO population), the proportion of subjects with HIV RNA <50 copies/mL at Week 48 was 123/186 (66%).
Danish: I en kombineret analyse af VIKING 3 og VIKING 4 (n=186, VO-population) var andelen af patienter med hiv-RNA < 50 kopier/ml ved uge 48 123 ud af 186 (66 %).
English: Cmax ↓ 72% (Complex binding to polyvalent ions)
Danish: Cmax  72 % (Kompleksbinding til polyvalente ioner)
English: • suicidal thoughts*
Danish: • selvmordstanker*
English: Response was associated with baseline INI mutation pathway, as shown in Table 7.
Danish: Respons var forbundet med INI-mutationsforløbet som vist i tabel 7.
English: Table 6 Response in SAILING at 48 Weeks (Snapshot algorithm, <50 copies/mL) Dolutegravir 50 mg Once Daily + BR N=354§
Danish: Tabel 6 Respons i SAILING efter 48 uger (snapshot-algoritme, < 50 kopier/ml) 50 mg dolutegravir en gang daglig + BR N = 354§
English: In the presence of documented resistance that includes Q148 + ≥2 secondary mutations from G140A/C/S, E138A/K/T, L74I, modelling suggests that an increased dose may be considered for patients with limited treatment options (less than 2 active agents) due to advanced multi class resistance (see section 5.2).
Danish: Ved dokumenteret resistens, som inkluderer Q148 + ≥2 sekundære mutationer fra G140A/C/S, E138A/K/T, L74I, antyder modeller, at en øget dosis kan overvejes til patienter med begrænsede behandlingsmuligheder (mindre end 2 aktive stoffer) som følge af fremskreden multiklasseresistens (se pkt.
English: Autoimmune disorders (such as Graves' disease and autoimmune hepatitis) have also been reported; however, the reported time to onset is more variable and these events can occur many months after initiation of treatment (see section 4.4).
Danish: Autoimmune forstyrrelser (f.eks. Graves' sygdom og autoimmun hepatitis) er også blevet rapporteret, men den rapporterede tid til indtrædelse svinger mere, og disse hændelser kan opstå mange måneder efter indledning af behandlingen (se pkt.
English: The primary effect of dolutegravir was gastrointestinal intolerance or irritation in rats and monkeys at doses that produce systemic exposures approximately 21 and 0.82 times the 50 mg twice daily human clinical exposure based on AUC, respectively.
Danish: Den primære effekt af dolutegravir var gastrointestinal intolerance eller irritation hos rotter og aber ved doser, der medfører systemiske eksponeringer på henholdsvis ca. 21 og 0,82 gange den humane kliniske eksponering ved 50 mg to gange daglig baseret på AUC.
English: Magnesium/ aluminium-containing antacid should be taken well separated in time from the administration of dolutegravir (minimum 2 hours after or 6 hours before).
Danish: Antacida indeholdende magnesium/aluminium skal tages tidsforskudt fra administrationen af dolutegravir (minimum 2 timer efter eller 6 timer før).
English: In SPRING-2, dolutegravir was still noninferior to raltegravir (viral suppression in 81% vs 76% of patients), and with a median change in CD4 count of 276 vs 264 cells/mm3, respectively.
Danish: I SPRING-2 var dolutegravir stadig non-inferior til relategravir (viral hæmning hos 81 % vs. 76 % af patienterne) og med en median ændring i CD4-celletallet på henholdsvis 276 vs. 264 celler/mm3.
English: Antimycobacterials Rifampicin
Danish: Antimykobakterielle midler Rifampicin
English: Alternative combinations that do not include these metabolic inducers should be used where possible in INIresistant patients.
Danish: Om muligt bør alternative kombinationer, som ikke inkluderer disse metaboliske inducere, anvendes til INI-resistente patienter.
English: Subjects were stratified by age, receiving Tivicay (70 mg, as 35 mg twice daily, n=1; 50 mg once daily, n=5; 35 mg once daily, n=6; 25 mg once daily, n= 8; and 20 mg once daily, n=3) plus OBR.
Danish: Patienterne blev stratificeret efter alder og fik Tivicay (70 mg, som 35 mg to gange daglig, n=1; 50 mg én gang daglig, n=5; 35 mg én gang daglig, n=6; 25 mg én gang daglig, n=8; eller 20 mg én gang daglig, n=3) plus OBR.
English: PK/PD modelling using pooled data from clinical studies in integrase resistant patients suggest that increasing the dose from 50 mg twice daily to 100 mg twice daily may increase the effectiveness of dolutegravir in patients with integrase resistance and limited treatment options due to advanced multi class resistance.
Danish: Farmakokinetisk/farmadynamisk modellering af de samlede data fra kliniske studier hos integraseresistente patienter antyder, at øgning af dosis fra 50 mg to gange daglig til 100 mg to gange daglig kan øge effektiviteten af dolutegravir hos patienter med integraseresistens og begrænsede behandlingsmuligheder som følge af fremskreden multiklasseresistens.
English: GlaxoSmithKline Slovakia s. r. o. Tel: + 421 (0)2 48 26 11 11 recepcia.sk@gsk.com
Danish: Slovenská republika GlaxoSmithKline Slovakia s. r. o. Tel: + 421 (0)2 48 26 11 11 recepcia.sk@gsk.com
English: Anticonvulsants Carbamazepine
Danish: Antikonvulsiva Carbamazepin
English: In the presence of integrase class resistance alternative combinations that do not include fosamprenavir/ritonavir should be considered.
Danish: Ved resistens over for integrasehæmmere bør der overvejes andre kombinationer uden fosamprenavir/ritonavir.
English: Calcium supplements, iron supplements or multivitamins Calcium supplements, iron supplements or multivitamins can stop Tivicay being absorbed into your body and make it less effective.
Danish: Calciumtilskud, jerntilskud eller multivitaminer kan modvirke optagelsen af Tivicay i kroppen og gøre det mindre effektivt.
English: Monitoring of liver biochemistries is recommended in patients with hepatitis B and/or C co-infection.
Danish: Det anbefales at monitorere biokemiske leverparametre hos patienter, der er coinficeret med hepatitis B- og/eller C-virus.
English: Dolutegravir and other suspect medicinal products should be discontinued immediately if signs or symptoms of hypersensitivity reactions develop (including, but not limited to, severe rash or rash accompanied by raised liver enzymes, fever, general malaise, fatigue, muscle or joint aches, blisters, oral lesions, conjunctivitis,
Danish: Dolutegravir og andre mistænkte lægemidler skal omgående seponeres, hvis der udvikles tegn eller symptomer på overfølsomhedsreaktioner (herunder, men ikke begrænset til, svært udslæt eller udslæt ledsaget af et øget niveau af leverenzymer, feber, generel utilpashed, træthed, muskel- eller ledsmerter, blærer, orale læsioner, konjunktivitis, ansigtsødem, eosinofili, angioødem).
English: In previously untreated patients receiving dolutegravir + 2 NRTIs in Phase IIb and Phase III, no development of resistance to the integrase class, or to the NRTI class was seen (n=1118 follow-up of 48-96 weeks).
Danish: Hos tidligere ubehandlede patienter, som fik dolutegravir + 2 NRTI'er i fase IIb og fase III, blev der ikke set udvikling af resistens over for integrasehæmmere eller over for NRTI-klassen (n = 1118 opfølgning på 48-96 uger).
English: Although these simulated results have not been confirmed in clinical trials, this high dose may be considered in the presence of the Q148 + ≥2 secondary mutations from G140A/C/S, E138A/K/T, L74I in patients with overall limited treatment options due to advanced multi class resistance.
Danish: Selvom disse simulerede resultater ikke er bekræftet i kliniske studier, kan denne dosis overvejes ved tilstedeværelse af Q148 + ≥2 sekundære mutationer i G140A/C/S, E138A/K/T, L74I hos patienter med generelt begrænsede behandlingsmuligheder som følge af fremskreden multiklasseresistens.
English: HIV-1 RNA <50 copies/mL at 24 weeks, n (%) HIV-1 RNA <50 copies/mL at 48 weeks, n (%) HIV-1 RNA <400 copies/mL at 24 weeks, n (%) HIV-1 RNA <400 copies/mL at 48 weeks, n (%) Virologic non response
Danish: Hiv-1-RNA < 50 kopier/ml ved uge 24, n (%) Hiv-1-RNA < 50 kopier/ml ved uge 48, n (%) Hiv-1-RNA < 400 kopier/ml ved uge 24, n (%) Hiv-1-RNA < 400 kopier/ml ved uge 48, n (%) Virologisk non-respons
English: EFV/TDF/FTC Once Daily N=419
Danish: EFV/TDF/FTC en gang daglig N = 419
English: The pharmacokinetics was evaluated in 11 children 6 to 12 years of age and showed that 25 mg once daily in patients weighing at least 20 kg and 35 mg once daily in patients weighing at least 30 kg resulted in dolutegravir exposure comparable to adults.
Danish: Farmakokinetikken blev evalueret hos 11 børn i alderen 6 til 12 år og viste, at 25 mg én gang dagligt hos patienter, som vejede mindst 20 kg, og 35 mg én gang dagligt hos patienter, som vejede mindst 30 kg, resulterede i en eksponering for dolutegravir, som var sammenlignelig med eksponeringen hos voksne.
English: At week 48, dolutegravir was non-inferior to raltegravir in the SPRING-2 study, and in the SINGLE study dolutegravir + ABC/3TC was superior to efavirenz/TDF/FTC (p=0.003), table 4 above.
Danish: Ved uge 48 var dolutegravir non-inferior til raltegravir i SPRING-2-studiet og i SINGLE-studiet var dolutegravir + ABC/3TC superior til efavirenz/TDF/FTC (p = 0,003), se tabel 4 ovenfor.
English: EU/1/13/892/004 EU/1/13/892/005 EU/1/13/892/006
Danish: EU/1/13/892/001 EU/1/13/892/002 EU/1/13/892/003 EU/1/13/892/004 EU/1/13/892/005 EU/1/13/892/006
English: Polyvinyl alcohol-partially hydrolyzed Titanium dioxide (E171)
Danish: Titandioxid (E171)
English: In animal reproductive toxicity studies, no adverse development outcomes, including neural tube defects, were identified (see section 5.3).
Danish: I studier af reproduktionstoksicitet hos dyr er der ikke set negative indvirkninger, herunder neuralrørsdefekter, på afkommets udvikling (se pkt.
English: This includes co-administration with medicinal products that reduce dolutegravir exposure (e.g. magnesium/ aluminium-containing antacid, iron and calcium supplements, multivitamins and inducing agents, etravirine (without boosted protease inhibitors), tipranavir/ritonavir, rifampicin, St. John's wort and certain antiepileptic medicinal products) (see section 4.5).
Danish: Dette inkluderer samtidig administration med lægemidler, der reducerer dolutegravireksponering (f.eks. antacida indeholdende magnesium/aluminium, jern- og calciumtilskud, multivitaminer og inducerende stoffer, etravirin (uden boostede proteasehæmmere) tipranavir/ritonavir, rifampicin, perikon og visse antiepileptiske lægemidler) (se pkt.